December 2019 - NERLYNX^® (neratinib) approved in Singapore for extended adjuvant therapy in HER2+/HR+ breast cancer

ST achieves approval to market NERLYNX^® (neratinib) in Singapore for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.